Cargando…

Measuring Opioid Withdrawal in a Phase 3 Study of a New Analgesic, NKTR-181 (Oxycodegol), in Patients with Moderate to Severe Chronic Low Back Pain

OBJECTIVE: To evaluate the SUMMIT-07 trial opioid withdrawal results of NKTR-181 (oxycodegol), a new molecular entity mu-opioid receptor agonist. DESIGN: Phase 3, enriched-enrollment, double-blind, randomized-withdrawal study in patients with chronic low back pain (CLBP). SETTING: Conducted in the U...

Descripción completa

Detalles Bibliográficos
Autores principales: Henningfield, Jack E, Gudin, Jeffrey, Rauck, Richard, Gimbel, Joseph, Tagliaferri, Mary, Doberstein, Stephen K, Di Fonzo, Carlo, Lu, Lin, Katz, Nathaniel, Siddhanti, Suresh, Schnoll, Sidney
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530570/
https://www.ncbi.nlm.nih.gov/pubmed/32150255
http://dx.doi.org/10.1093/pm/pnz326
_version_ 1783589593654755328
author Henningfield, Jack E
Gudin, Jeffrey
Rauck, Richard
Gimbel, Joseph
Tagliaferri, Mary
Doberstein, Stephen K
Di Fonzo, Carlo
Lu, Lin
Katz, Nathaniel
Siddhanti, Suresh
Schnoll, Sidney
author_facet Henningfield, Jack E
Gudin, Jeffrey
Rauck, Richard
Gimbel, Joseph
Tagliaferri, Mary
Doberstein, Stephen K
Di Fonzo, Carlo
Lu, Lin
Katz, Nathaniel
Siddhanti, Suresh
Schnoll, Sidney
author_sort Henningfield, Jack E
collection PubMed
description OBJECTIVE: To evaluate the SUMMIT-07 trial opioid withdrawal results of NKTR-181 (oxycodegol), a new molecular entity mu-opioid receptor agonist. DESIGN: Phase 3, enriched-enrollment, double-blind, randomized-withdrawal study in patients with chronic low back pain (CLBP). SETTING: Conducted in the United States at multiple sites. METHODS: SUMMIT-07 was comprised of five periods: screening; NKTR-181 open-label titration (100 to 400 mg twice daily); 12-week randomized, double-blind study drug (NKTR-181 or placebo); one-week study drug taper; and two-week safety follow-up. Permitted rescue medication included hydrocodone 5 mg/acetaminophen 300 mg (two tablets daily) for two weeks after randomization, then acetaminophen 1.0 gm daily for the remainder of the trial. Signs and symptoms of drug withdrawal were evaluated using the Clinical Opiate Withdrawal Scale (COWS); Subjective Opiate Withdrawal Scale (SOWS); Misuse, Abuse, and Diversion Drug Event Reporting System (MADDERS); and withdrawal-related adverse events. RESULTS: Of 1,190 patients entering titration, one patient had moderate withdrawal (COWS score 13/48 maximum) three days after discontinuing NKTR-181. Of 610 patients randomized (N = 309, NKTR-181; N = 301, placebo), no COWS scores indicating withdrawal at a moderate level or greater (i.e., score ≥13) were observed at any time point. At day 8 after randomization, week 12, and the end of tapering, COWS scores indicating mild withdrawal (<13) were observed in seven (2.4%), one (0.4%), and one (0.5%) placebo patients, respectively, and three (1.0%), one (0.4%), and five (2.3%) NKTR-181 patients, respectively. Mean SOWS scores in both arms were ≤2.8 of 64 possible points at all time points. During the randomized period, of 35 events identified by MADDERS, adjudicators identified 20 possible “withdrawal” events (9 [2.9%] NKTR-181 and 11 [3.7%] placebo). CONCLUSIONS: NKTR-181 exhibited a low rate and severity of opioid withdrawal in SUMMIT-07 patients with CLBP.
format Online
Article
Text
id pubmed-7530570
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-75305702020-10-07 Measuring Opioid Withdrawal in a Phase 3 Study of a New Analgesic, NKTR-181 (Oxycodegol), in Patients with Moderate to Severe Chronic Low Back Pain Henningfield, Jack E Gudin, Jeffrey Rauck, Richard Gimbel, Joseph Tagliaferri, Mary Doberstein, Stephen K Di Fonzo, Carlo Lu, Lin Katz, Nathaniel Siddhanti, Suresh Schnoll, Sidney Pain Med Opioids & Substance Use Disorders Section OBJECTIVE: To evaluate the SUMMIT-07 trial opioid withdrawal results of NKTR-181 (oxycodegol), a new molecular entity mu-opioid receptor agonist. DESIGN: Phase 3, enriched-enrollment, double-blind, randomized-withdrawal study in patients with chronic low back pain (CLBP). SETTING: Conducted in the United States at multiple sites. METHODS: SUMMIT-07 was comprised of five periods: screening; NKTR-181 open-label titration (100 to 400 mg twice daily); 12-week randomized, double-blind study drug (NKTR-181 or placebo); one-week study drug taper; and two-week safety follow-up. Permitted rescue medication included hydrocodone 5 mg/acetaminophen 300 mg (two tablets daily) for two weeks after randomization, then acetaminophen 1.0 gm daily for the remainder of the trial. Signs and symptoms of drug withdrawal were evaluated using the Clinical Opiate Withdrawal Scale (COWS); Subjective Opiate Withdrawal Scale (SOWS); Misuse, Abuse, and Diversion Drug Event Reporting System (MADDERS); and withdrawal-related adverse events. RESULTS: Of 1,190 patients entering titration, one patient had moderate withdrawal (COWS score 13/48 maximum) three days after discontinuing NKTR-181. Of 610 patients randomized (N = 309, NKTR-181; N = 301, placebo), no COWS scores indicating withdrawal at a moderate level or greater (i.e., score ≥13) were observed at any time point. At day 8 after randomization, week 12, and the end of tapering, COWS scores indicating mild withdrawal (<13) were observed in seven (2.4%), one (0.4%), and one (0.5%) placebo patients, respectively, and three (1.0%), one (0.4%), and five (2.3%) NKTR-181 patients, respectively. Mean SOWS scores in both arms were ≤2.8 of 64 possible points at all time points. During the randomized period, of 35 events identified by MADDERS, adjudicators identified 20 possible “withdrawal” events (9 [2.9%] NKTR-181 and 11 [3.7%] placebo). CONCLUSIONS: NKTR-181 exhibited a low rate and severity of opioid withdrawal in SUMMIT-07 patients with CLBP. Oxford University Press 2020-08 2020-03-09 /pmc/articles/PMC7530570/ /pubmed/32150255 http://dx.doi.org/10.1093/pm/pnz326 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of the American Academy of Pain Medicine. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License(http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Opioids & Substance Use Disorders Section
Henningfield, Jack E
Gudin, Jeffrey
Rauck, Richard
Gimbel, Joseph
Tagliaferri, Mary
Doberstein, Stephen K
Di Fonzo, Carlo
Lu, Lin
Katz, Nathaniel
Siddhanti, Suresh
Schnoll, Sidney
Measuring Opioid Withdrawal in a Phase 3 Study of a New Analgesic, NKTR-181 (Oxycodegol), in Patients with Moderate to Severe Chronic Low Back Pain
title Measuring Opioid Withdrawal in a Phase 3 Study of a New Analgesic, NKTR-181 (Oxycodegol), in Patients with Moderate to Severe Chronic Low Back Pain
title_full Measuring Opioid Withdrawal in a Phase 3 Study of a New Analgesic, NKTR-181 (Oxycodegol), in Patients with Moderate to Severe Chronic Low Back Pain
title_fullStr Measuring Opioid Withdrawal in a Phase 3 Study of a New Analgesic, NKTR-181 (Oxycodegol), in Patients with Moderate to Severe Chronic Low Back Pain
title_full_unstemmed Measuring Opioid Withdrawal in a Phase 3 Study of a New Analgesic, NKTR-181 (Oxycodegol), in Patients with Moderate to Severe Chronic Low Back Pain
title_short Measuring Opioid Withdrawal in a Phase 3 Study of a New Analgesic, NKTR-181 (Oxycodegol), in Patients with Moderate to Severe Chronic Low Back Pain
title_sort measuring opioid withdrawal in a phase 3 study of a new analgesic, nktr-181 (oxycodegol), in patients with moderate to severe chronic low back pain
topic Opioids & Substance Use Disorders Section
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530570/
https://www.ncbi.nlm.nih.gov/pubmed/32150255
http://dx.doi.org/10.1093/pm/pnz326
work_keys_str_mv AT henningfieldjacke measuringopioidwithdrawalinaphase3studyofanewanalgesicnktr181oxycodegolinpatientswithmoderatetoseverechroniclowbackpain
AT gudinjeffrey measuringopioidwithdrawalinaphase3studyofanewanalgesicnktr181oxycodegolinpatientswithmoderatetoseverechroniclowbackpain
AT rauckrichard measuringopioidwithdrawalinaphase3studyofanewanalgesicnktr181oxycodegolinpatientswithmoderatetoseverechroniclowbackpain
AT gimbeljoseph measuringopioidwithdrawalinaphase3studyofanewanalgesicnktr181oxycodegolinpatientswithmoderatetoseverechroniclowbackpain
AT tagliaferrimary measuringopioidwithdrawalinaphase3studyofanewanalgesicnktr181oxycodegolinpatientswithmoderatetoseverechroniclowbackpain
AT dobersteinstephenk measuringopioidwithdrawalinaphase3studyofanewanalgesicnktr181oxycodegolinpatientswithmoderatetoseverechroniclowbackpain
AT difonzocarlo measuringopioidwithdrawalinaphase3studyofanewanalgesicnktr181oxycodegolinpatientswithmoderatetoseverechroniclowbackpain
AT lulin measuringopioidwithdrawalinaphase3studyofanewanalgesicnktr181oxycodegolinpatientswithmoderatetoseverechroniclowbackpain
AT katznathaniel measuringopioidwithdrawalinaphase3studyofanewanalgesicnktr181oxycodegolinpatientswithmoderatetoseverechroniclowbackpain
AT siddhantisuresh measuringopioidwithdrawalinaphase3studyofanewanalgesicnktr181oxycodegolinpatientswithmoderatetoseverechroniclowbackpain
AT schnollsidney measuringopioidwithdrawalinaphase3studyofanewanalgesicnktr181oxycodegolinpatientswithmoderatetoseverechroniclowbackpain